| Literature DB >> 30328339 |
M A Shehab1, Tahseen Mahmood1, M A Hasanat1, Md Fariduddin1, Nazmul Ahsan2, Mohammad Shahnoor Hossain2, Md Shahdat Hossain2, Sharmin Jahan1.
Abstract
Congenital adrenal hyperplasia (CAH) due to the three-beta-hydroxysteroid-dehydrogenase (3β-HSD) enzyme deficiency is a rare autosomal recessive disorder presenting with sexual precocity in a phenotypic male. Klinefelter syndrome (KS) is the most common sex chromosome aneuploidy presenting with hypergonadotropic hypogonadism in a male. However, only a handful of cases of mosaic KS have been described in the literature. The co-existence of mosaic KS with CAH due to 3β-HSD enzyme deficiency portrays a unique diagnostic paradox where features of gonadal androgen deficiency are masked by simultaneous adrenal androgen excess. Here, we report a 7-year-old phenotypic male boy who, at birth presented with ambiguous genitalia, probably a microphallus with penoscrotal hypospadias. Later on, he developed accelerated growth with advanced bone age, premature pubarche, phallic enlargement and hyperpigmentation. Biochemically, the patient was proven to have CAH due to 3β-HSD deficiency. However, the co-existence of bilateral cryptorchidism made us to consider the possibility of hypogonadism as well, and it was further explained by concurrent existence of mosaic KS (47,XXY/46,XX). He was started on glucocorticoid and mineralocorticoid replacement and underwent right-sided orchidopexy on a later date. He showed significant clinical and biochemical improvement on subsequent follow-up. However, the declining value of serum testosterone was accompanied by rising level of FSH thereby unmasking hypergonadotropic hypogonadism due to mosaic KS. In future, we are planning to place him on androgen replacement as well. Learning points: •• Ambiguous genitalia with subsequent development of sexual precocity in a phenotypic male points towards some unusual varieties of CAH. •• High level of serum testosterone, adrenal androgen, plasma ACTH and low basal cortisol are proof of CAH, whereas elevated level of 17-OH pregnenolone is biochemical marker of 3β-HSD enzyme deficiency. •• Final diagnosis can be obtained with sequencing of HSD3B2 gene showing various mutations. •• Presence of bilateral cryptorchidism in such a patient may be due to underlying hypogonadism. •• Karyotyping in such patient may rarely show mosaic KS (47,XXY/46,XX) and there might be unmasking of hypergonadotropic hypogonadism resulting from adrenal androgen suppression from glucocorticoid treatment.Entities:
Year: 2018 PMID: 30328339 PMCID: PMC6198180 DOI: 10.1530/EDM-18-0108
Source DB: PubMed Journal: Endocrinol Diabetes Metab Case Rep ISSN: 2052-0573
Figure 1Pedigree chart of the subject.
Figure 2Front profile of the boy.
Figure 3Phallic enlargement.
Figure 4Appearance of external genitalia.
Initial hormonal status of the subject.
| Hormonal assay | Test result | Reference value |
|---|---|---|
| Serum LH (mIU/mL) | 0.19 | ≤0.44 |
| Serum FSH (IU/L) | 3.83 | <3 |
| Serum testosterone (ng/dL) | 276 | ≤42 |
| Serum testosterone (following hCG) (ng/dL) | 561.63 | NA |
| Serum estradiol (pg/mL) | 11.8 | ≤4 |
| Basal cortisol (nmol/L) | 129 | 138–690 |
| Plasma ACTH (pg/mL) | 269 | 0.00–46 |
| 17-OH-progesterone (ng/mL) | 2.15 | 0.5–2.1 |
| 17-OH-pregnenolone (ng/dL) | 2097 | ≤72 |
| DHEA-S (µg/dL) | 331.80 | <186 |
| Androstenedione (ng/dL) | 34 | 6–115 |
Figure 5CT scan of adrenal glands.
Figure 6Partial nucleotide sequences of HSD3B2 gene showing in black arrows the homozygous G>A transversion (A) and heterozygous A>G transversion and T>A transition (B) in antisense strands. Upper panels in small letters show the complimentary sequences of the nucleotides and the three letter blocks show the respective amino acids.
Figure 7Intra-abdominal testis on right side.
Hormonal profile following 6 months of suppressive glucocorticoid therapy.
| Hormonal assay | After treatment | Before treatment |
|---|---|---|
| Serum LH (mIU/mL) | 3.05 | 0.19 |
| Serum FSH (IU/L) | 13.96 | 3.83 |
| Serum testosterone (ng/dL) | 107.50 | 276 |
| Plasma ACTH (pg/mL) | 7.19 | 269 |
| DHEA-S (µg/dL) | 26.70 | 331.80 |